Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at preventing migraine. The drug was built with a half‑life extension for subcutaneous dosing, a design choice meant to make at‑home injections realistic for patients who still are not getting what they need from current preventive therapies.
The round was co‑led by RA Capital Management, Forbion and Foresite Capital, with one additional biotech investor choosing to stay in the background, according to a company release. The raise was announced via a press release on Business Wire.
The Drug And The Plan
Slate’s lead asset, SLTE‑1009 (also known as DS009), goes after pituitary adenylate cyclase‑activating polypeptide (PACAP), a pathway different from the CGRP inhibitors that dominate today’s migraine-prevention market. The antibody was engineered for a longer half‑life and subcutaneous dosing, and Slate expects to kick off a Phase 1 study in mid‑2026, as reported by Fierce Biotech.
Leadership And Board Moves
The company is led by CEO Gregory Oakes and COO Neil Buckley. With the new financing comes fresh oversight in the boardroom: Andrew Levin of RA Capital, Tim Lohoff of Forbion and Cindy Xiong of Foresite Capital are all taking seats. Slate said it was co‑founded with RA Capital’s Sera Medicines accelerator, and that Cooley LLP advised on the deal, according to Business Wire.
Why PACAP Is Getting Attention
PACAP blockade has developed a bit of a reputation as a high‑risk, high‑reward migraine strategy. Some earlier programs struggled to show clear benefit with subcutaneous formulations, which cooled enthusiasm for a while. But recent intravenous data have pulled the pathway back into the spotlight. Industry reporting notes that Lundbeck’s IV anti‑PACAP hit its Phase 2b endpoint, while earlier subcutaneous efforts at Amgen and Eli Lilly did not, which helps explain why investors are ready to fund another run at the target, per Fierce Biotech.
What Comes Next
Slate says the new capital will go toward expanding operations and R&D as it gears up for first‑in‑human testing. Details like dose range, dosing schedule and clinical sites are expected to come into focus as the Phase 1 protocol is locked in. The funding and licensing move have been noted across the industry, with coverage from FinSMEs and Axios, underscoring that investors are still hunting for fresh options for patients who do not respond to what is already on the shelf.
